3 New MAs Strengthen Farmak International’s Czech Footprint
Levosimendan IV, Gadoteric Acid MRI contrast, and Linagliptin tablets boost portfolio to 50+ SKUs / 16 brands; Farmak International invites new distribution and tender partners
Farmak International, the global-markets arm of Farmak Group, today announced it has secured 3 new Marketing Authorisations (MAs) from the State Institute for Drug Control (SÚKL). Granted in mid-late spring 2025, the approvals cover:
• Levosimendan injection – in-hospital inotrope for acute decompensated heart failure (launch targeted Dec 2025 / Jan 2026)
• Gadoteric Acid injection – macrocyclic MRI contrast agent for radiology centers (Sept 2025 launch)
• Linagliptin 5 mg tablets – DPP-4 inhibitor for type 2 diabetes (commercial rollout date forthcoming)
These additions bring Farmak International’s Czech portfolio to 50+ SKUs / 16 brands in various therapeutic areas: gastroenterology, urology, cough & cold, and allergology, and more.
Partnership Opportunities
Hospital procurement groups, radiology networks and retail-pharmacy distributors interested in collaborating on these launches are invited to email bd@farmak.ch or submit an enquiry via https://farmak.ch/contact-us/.
Important Information for Healthcare Professionals
This announcement contains information on products intended for healthcare professionals only. Levosimendan injection, Gadoteric Acid injection and Linagliptin 5 mg tablets are prescription-only medicines and must be prescribed and administered by qualified medical personnel in appropriate clinical settings. Always refer to the full Summary of Product Characteristics (SmPC) and relevant national prescribing guidelines.
About Farmak Group and Farmak International
Since 1925, Farmak Group has grown into a worldwide pharmaceutical business, globally represented by Farmak International. Today, it operates modern production facilities in two European countries and manages 13 corporate entities and representative offices spanning Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, Moldova, Spain and Ukraine. Its products reach 60 countries across Europe, Asia, the Middle East & Africa (MEA), and Latin America, supported by a robust supply-chain network and longstanding alliances with healthcare providers and distributors worldwide.
With a diversified generics portfolio, ongoing investments in R&D, and a proven record of successful market entries, Farmak International partners with healthcare stakeholders to ensure timely, reliable access to essential therapies.
